Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2026-03-26 @ 3:16 PM
Ignite Modification Date:
2026-03-26 @ 3:16 PM
NCT ID:
NCT07395232
Brief Summary:
This is a phase 3, multicenter, randomized, double-masked, parallel-group, vehicle-controlled study to evaluate the safety and efficacy of DFL24498 compared with vehicle ophthalmic solution, in participants with AKC. Approximately 138 participants who meet all eligibility criteria will be enrolled in the study.
Detailed Description:
The study will consist of 3 periods:
1. Screening period (from Day -7 ± 1 to Day 1),
2. Treatment Period (from randomization through Week12) and
3. Follow-up period (Weeks 13 to 16).
Study:
NCT07395232
Study Brief:
Protocol Section:
NCT07395232